Deep coma in a child treated with propranolol for infantile hemangioma

Area of Science:

• Pediatric Pharmacology
• Dermatology
• Neonatology

Background:

• Propranolol hydrochloride is the primary treatment for infantile hemangiomas (IH).
• Serious adverse effects associated with propranolol therapy for hemangiomas are generally infrequent.
• Infantile hemangiomas require prompt and effective management due to potential complications.

Observation:

• A case of deep hypoglycemic coma during propranolol treatment for infantile hemangiomas is presented.
• This case highlights a rare but severe adverse effect of propranolol in pediatric patients.
• The patient's condition necessitated immediate medical intervention.

Findings:

• Propranolol therapy, while effective for IH, carries a risk of life-threatening adverse events.
• Hypoglycemia can be a critical complication in infants treated with propranolol.
• Vigilance for adverse effects is essential despite the drug's established safety profile.

Implications:

• Pediatricians must be aware of and prepared to manage severe adverse effects of propranolol.
• Early identification of adverse events is crucial for improving patient outcomes and prognosis.
• Educating parents about potential risks and symptoms is paramount for timely intervention.